217亿美元巨头：辉瑞Upjohn和Mylan合并推迟
2020年3月26日，辉瑞和Mylan（迈蓝）宣布，鉴于此次新型冠状病毒肺炎疫情相关形势紧张，辉瑞Upjohn（普强）和Mylan（迈蓝）的合并交易现在预期将于2020年下半年结束。
鉴于全球旅行和集会方面的限制，Mylan股东对于此次交易的投票的特别股东大会将在2020年6月30日（原定于4月27日）举行。
此前的时间表
为适应这些变化，辉瑞已经与迈蓝达成共识，把内部运营准备就绪的目标日期由今年6月1日改为9月1日，这是考虑到目前的工作条件、以及疫情相关的竞争性活动影响到两家公司的生产与数字化系统/团队。这是意料中的变化。大多数公司的业务和其它交易，也都类似地受到了这次新冠病毒疫情的影响。
2019年7月29日，迈蓝和辉瑞宣布了以下最终协议：将迈蓝与辉瑞旗下专利到期品牌和仿制药业务部门—普强合并，以创建一家新的全球制药公司。根据结构为全股票、反向莫里斯信托交易的协议条款，每股迈蓝股票将转换成新公司的一股股票。辉瑞股东将拥有合并后新公司57％的股份，而迈蓝股东将拥有43％的股份。迈蓝和辉瑞的董事会已一致批准了这项交易。
通过将两个高度互补的业务的结合，新公司将转型并加快各自业务满足患者需求的业务能力，扩展他们在超过165个市场的能力。迈蓝为各个关键治疗领域，如中枢神经系统和麻醉、传染病和心血管疾病带来多元化的产品组合，以及强大的产品管线、高质量的制造与供应链优势。普强则带来了值得信赖的标志性品牌，如立普妥（阿托伐他汀钙）、西乐葆（塞来昔布）和万艾可（西地那非）等，以及业经证明的商业化能力，包括在中国和其他新兴市场的领导地位。
此次交易将使新公司显著扩展迈蓝现有广泛产品组合的区域覆盖范围和未来产品管线——包括在复杂仿制药和生物类似药方面对普强目前拥有销售基础设施和当地市场专业经验的新增长市场进行重大投资 。
2019年11月，辉瑞普强（Upjohn）和迈蓝（Mylan）宣布合并的公司名为Viatris（发音为‘viǝ-trīs）。2020年完成交易后，届时制药巨头将以Viatris名字出现。
Mylan 2019财年业绩，营收115亿美元，同比增长1%。
辉瑞2019业绩，其中：辉瑞普强营收102.33亿美元，同比下降16%。
附，原文：
Mar. 26, 2020-- Mylan N.V. (Nasdaq: MYL) and Pfizer Inc. (NYSE: PFE) today announced that due to the unprecedented circumstances surrounding the COVID-19 pandemic, including associated delays in the regulatory review process, the proposed transaction involving Mylan and Upjohn, a division of Pfizer, is now anticipated to close in the second half of 2020.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200326005190/en/.
There are no additional changes to the previously announced terms or plans regarding the transaction. The two companies remain highly confident in the benefits of the pending transaction to their respective shareholders and other stakeholders. Mylan, Pfizer and Upjohn are working closely on integration planning and are making significant progress toward Day 1 readiness. Together the companies continue to progress toward a successful close.
The primary focus of both companies remains the health and safety of their dedicated and valued employees who are working tirelessly towards completion of this transaction while also maintaining their responsibility to meet patient needs during this extraordinary time.
Also, in light of increased meeting and other restrictions due to COVID-19 developments in the Netherlands, where Mylan is incorporated, Mylan’s extraordinary general meeting of shareholders (the “EGM”) to approve certain matters in connection with the transaction has been rescheduled from April 27, 2020, to June 30, 2020, and will be hosted in conjunction with the company’s annual general meeting of shareholders (the “AGM”) which is being scheduled for the same day. Accordingly, the record date for the EGM and the AGM in respect of Mylan’s ordinary shares is June 2, 2020 and the cut-off time for the EGM and the AGM – which is the time prior to which holders of Mylan ordinary shares can give notice of attendance at the applicable meeting or vote by internet or telephone or by submitting a proxy card - is 5:00 p.m. Central European Summer Time (CEST) on June 29, 2020. Further details about the time and location of the EGM and AGM will be announced once those have been finalized.
Mylan and Pfizer continue to look forward to the proposed combination creating a new champion for global health at the close of this transaction.For more information visit championforglobalhealth.com.
参考：
NMPA/CDE；
药融圈数据；
FDA/EMA；
相关公司公开披露；
https://www.championforglobalhealth.com/viatris/；
https://investors.pfizer.com/investor-news/press-release-details/2019/PFIZER-REPORTS-FOURTH-QUARTER-AND-FULL-YEAR-2018-RESULTS/default.aspx;
https://www.businesswire.com/news/home/20191112005863/en/Mylan-Pfizer-Announce-Viatris-New-Company-Planned?from=timeline#.XctUk5qWFTY.linkedin；
https://investor.mylan.com/等等。
RECOMMEND
本周推荐阅读
药融圈致力于打造医药行业生态圈，共建、共创、共赢、共享，旨在解决生物医药发展过程中的共性关键问题(项目、资本、人才等)，将平台的协同、联动、共享、共赢优势最大化实现并发挥，惠及千万企业。对大企业实现加速赋能，对中小企业实现助力孵化，形成企业服务领域新生态。药融圈围绕我国生物医药产业链，针对生物医药大数据、技术和资本投资、药融园(产业园)等开展系列系统性工作，促进我国生物医药产业健康发展，完善产业链，共同面对全球合作和竞争。